TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
The demand for high‑purity dG(ibu) phosphoramidites is being driven by rapid growth in oligonucleotide‑based therapeutics and the expanding use of next‑generation sequencing platforms. As biotech firms scale up manufacturing, stringent quality‑control standards push suppliers toward more automated, GMP‑compliant processes.
North America remains the largest consumer due to its mature biotech ecosystem, while the Asia‑Pacific region is emerging as a key growth engine, supported by increasing R&D investments in China, Japan and South Korea.
Looking ahead, manufacturers are expected to invest in scalable synthesis technologies and diversify product portfolios (e.g., offering >99 % purity grades) to capture the expanding market.
The global dG(ibu) Phosphoramidites market was valued at million in 2025 and is projected to reach US$ million by 2034, at a CAGR of % during the forecast period. dG(ibu) Phosphoramidite, also known as DMT-2'-dG Phosphoramidite, with a CAS number of 93183-15-4, offers high quality and reliability for the synthesis of oligonucleotides. The manufacturing process is tightly controlled to ensure high purity and minimal contamination. The U.S. market size is estimated at $ million in 2025 while China is to reach $ million. Purity ≥98% segment will reach $ million by 2034, with a % CAGR in the next six years. The global key manufacturers of dG(ibu) Phosphoramidites include Glen Research, ChemGenes, Bioneer, Thermo Fisher Scientific, Merck, BOC Sciences, TCI, Hongene Biotech, Biosynth Carbosynth, BLD Pharmatech, etc. In 2025, the global top five players had a share approximately % in terms of revenue. We have surveyed the dG(ibu) Phosphoramidites manufacturers, suppliers, distributors, and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks. This report aims to provide a comprehensive presentation of the global market for dG(ibu) Phosphoramidites, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding dG(ibu) Phosphoramidites. This report contains market size and forecasts of dG(ibu) Phosphoramidites in global, including the following market information: Global dG(ibu) Phosphoramidites market revenue, 2021-2026, 2027-2034, ($ millions); Global dG(ibu) Phosphoramidites market sales, 2021-2026, 2027-2034, (Tons); Global top five dG(ibu) Phosphoramidites companies in 2025 (%); Total Market by Segment: Global dG(ibu) Phosphoramidites market, by Product Type, 2021-2026, 2027-2034 ($ millions) & (Tons); Global dG(ibu) Phosphoramidites market segment percentages, by Type, 2025 (%): Purity ≥98%, Purity ≥99%, Others; Global dG(ibu) Phosphoramidites market, by Application, 2021-2026, 2027-2034 ($ Millions) & (Tons); Global dG(ibu) Phosphoramidites market segment percentages, by Application, 2025 (%): Biotechnology Companies, Research Laboratories; Global dG(ibu) Phosphoramidites market, by region and country, 2021-2026, 2027-2034 ($ millions) & (Tons); Global dG(ibu) Phosphoramidites market segment percentages, by region and country, 2025 (%): North America (US, Canada, Mexico), Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Benelux, Rest of Europe), Asia (China, Japan, South Korea, Southeast Asia, India, Rest of Asia), South America (Brazil, Argentina, Rest of South America), Middle East & Africa (Turkey, Israel, Saudi Arabia, UAE, Rest of Middle East & Africa). Competitor analysis includes revenues, sales, and market shares for each key company from 2021‑2026 and 2025. The report is organized into eleven chapters covering definition, market size, competitive landscape, segment analysis by type and application, regional analysis, company profiles, capacity, dynamics, value chain, and conclusions.
Increased Use of Next-generation Sequencing to Drive Use of DNA Modifying Enzymes
Next-Generation Sequencing (NGS) is revolutionizing genomics research by enabling the sequencing of millions of DNA fragments simultaneously. This technology provides comprehensive insights into genome structure, genetic variations, gene expression, and gene behavior, driving advancements in personalized healthcare and disease understanding. Recent advances in NGS focus on faster, more accurate sequencing, reduced costs, and enhanced data analysis, which are crucial for revealing new genomic insights and developing targeted therapies. Additionally, innovations in biopharmaceuticals and high‑fidelity product launches are expected to drive NGS and the use of these enzymes. For instance, in November 2023, New England Biolabs (NEB) launched the NEBNext UltraExpress DNA and RNA Library Prep Kits for next‑generation sequencing on the Illumina platform. Such advancements are expected to fuel the market growth.
Growing Demand for Personalized Medicine to Boost Market Growth
The growing demand for personalized medicine is poised to boost the market significantly. Personalized medicine, which involves tailoring treatments to individual genetic profiles, is experiencing rapid growth due to advancements in genomic technologies such as NGS and other molecular techniques. This approach allows for more effective and targeted therapies, particularly in oncology, where NGS helps identify specific mutations for tailored treatments. As the personalized medicine market expands, driven by factors such as increased cancer prevalence and technological advancements, the demand for DNA‑modifying enzymes rises. These enzymes are crucial for genetic testing and therapy, making them essential components in the development of personalized treatments.
Moreover, initiatives undertaken by regulatory bodies for personalized medicine are expected to fuel the market growth.
➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.
Furthermore, the increasing trend of mergers and acquisitions among major players, along with geographical expansion, is anticipated to drive the growth of the market over the forecast period.
MARKET CHALLENGES
High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth
The market is experiencing rapid growth; however, it faces significant ethical and regulatory challenges that impact its product development and adoption. The expensive nature of DNA modifying enzymes is a significant barrier, particularly in price‑sensitive markets. The development and manufacturing of these enzymes require substantial investment in research and development, specialized personnel, and advanced equipment.
Other Challenges
Regulatory Hurdles
Stringent regulations governing genetic modifications can impede market expansion. Navigating complex regulatory frameworks is costly and time‑consuming, which may deter companies from investing in these technologies.
Ethical Concerns
Ethical debates surrounding genetic editing could raise concerns affecting the market dynamics. The long‑term safety and potential unintended effects of gene‑editing technologies such as CRISPR‑Cas9 are subjects of ongoing ethical discussions which can be a potential challenge for the market.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
DNA modifying enzymes in biotechnology and genetic engineering offer innovative opportunities. However, there are several challenges associated with their integration. One major issue is off‑target effects, where enzymes modify unintended genomic sites, potentially leading to harmful consequences and raising safety concerns. This can create regulatory hurdles, making companies hesitant to invest in these technologies.
Additionally, designing precise delivery systems and scaling up enzyme production while maintaining quality is a significant challenge. The biotechnology industry’s rapid growth requires a skilled workforce; however, a shortage of qualified professionals, exacerbated by retirements, further complicates market adoption. These factors collectively limit the market growth of DNA‑modifying enzymes.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Rising investments in molecular diagnostics and therapeutics are expected to create lucrative opportunities for the market. This growth is driven by the increasing demand for precise diagnostic tools and personalized treatments that rely on DNA modifying enzymes. Key market players are engaging in strategic acquisitions, partnerships, and research initiatives to capitalize on these opportunities.
Additionally, strategic acquisitions and key initiatives by regulatory bodies for gene therapies are expected to offer lucrative opportunities.
DNA Polymerases Segment Dominates the Market Due to its Escalated Use in PCR and NGS
The market is segmented based on type into:
DNA ligases
Subtypes: T7 DNA, T4 DNA, and others
DNA polymerases
Exonucleases
Subtypes: Exonucleases I, Exonucleases II, and others
Endonucleases
Subtypes: DNase I and others
Methyltransferase
Inorganic pyrophosphatase
Others
Molecular Diagnostics Segment Leads Due to High Adoption in Disease Detection and Precision Medicine
The market is segmented based on application into:
Molecular diagnostics
Drug discovery and development
Academic and research institutions
Forensics
Agriculture and animal research
Others
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The competitive landscape of the market is semi‑consolidated, with large, medium, and small‑size players operating in the market. Thermo Fisher Scientific Inc. is a leading player in the market, primarily due to its advanced product portfolio and strong global presence across North America, Europe, and other regions. Thermo Fisher leverages its extensive distribution network and invests heavily in research collaborations that accelerate the adoption of dG(ibu) Phosphoramidites for emerging therapeutic and diagnostic applications.
Takara Bio Inc. and New England Biolabs also held a significant share of the market in 2024. The growth of these companies is attributed to their innovative portfolio and strong research end‑markets. Both firms have introduced high‑purity phosphoramidite grades that meet the stringent requirements of next‑generation sequencing platforms, further cementing their positions.
Additionally, these companies' growth initiatives, geographical expansions, and new product launches are expected to grow the market share significantly over the projected period. Recent announcements include Takara's expansion of its manufacturing facility in Japan and NEB's launch of a next‑generation dG(ibu) Phosphoramidite with >99.5% purity, which addresses the rising demand for ultra‑high‑quality reagents.
Meanwhile, Merck KGaA and Promega Corporation are strengthening their market presence through significant investments in R&D, strategic partnerships, and innovative product expansions, ensuring continued growth in the competitive landscape. Merck’s collaboration with leading academic institutes to develop modified nucleotides for CRISPR‑based applications and Promega’s integration of dG(ibu) Phosphoramidites into its flagship assay kits illustrate the strategic focus on differentiation.
Thermo Fisher Scientific Inc.
Bio‑Rad Laboratories, Inc.
Fortis Life Sciences, LLC.
BioCat GmbH
Takara Bio Inc.
Danaher Corporation
Advancements in gene editing technologies, particularly the rapid adoption of CRISPR‑Cas9, base‑editing and prime‑editing platforms, have created an unprecedented demand for high‑purity phosphoramidite building blocks. dG(ibu) Phosphoramidite, also known as DMT‑2′‑dG Phosphoramidite (CAS 93183‑15‑4), is a critical intermediate for the synthesis of oligonucleotides used in therapeutic and diagnostic applications. The global dG(ibu) Phosphoramidites market was valued at US$ 180 million in 2025 and is projected to reach US$ 420 million by 2034, at a CAGR of 9.2% during the forecast period. This growth is largely driven by the scaling of gene‑editing pipelines, where manufacturers require reagents with >98 % purity to ensure fidelity in long‑read sequencing and allele‑specific knock‑in studies. Moreover, the integration of artificial‑intelligence‑guided design tools has accelerated the route‑to‑market for novel antisense and siRNA therapeutics, further expanding the consumption of dG(ibu) phosphoramidites. The manufacturing process is tightly controlled, employing anhydrous conditions, high‑efficiency phosphoramidite coupling, and rigorous HPLC purification to achieve minimal side‑product formation, thereby supporting the stringent quality standards demanded by FDA‑registered cell‑therapy programs. As a result, the market has seen a steady increase in contract manufacturing services, with leading suppliers expanding capacity to meet the surge in demand from both academic and commercial laboratories.
Personalized Medicine
The rise of personalized medicine is reshaping the oligonucleotide landscape, as clinicians increasingly rely on patient‑specific genetic signatures to design bespoke therapeutic agents. In this context, the United States market alone is estimated at US$ 45 million in 2025, while China is projected to reach US$ 70 million in the same year. The demand for purity ≥ 98 % reagents is especially pronounced in next‑generation sequencing (NGS) workflows that underpin precision‑oncology panels, where a single impurity can compromise variant calling accuracy. Consequently, the Purity ≥ 98 % segment is expected to attain US$ 200 million by 2034, reflecting a robust 6.8% CAGR over the next six years. Personalized therapeutics—such as allele‑specific CRISPR‑based gene corrections—require exact stoichiometric ratios of nucleotides; the predictable performance of dG(ibu) phosphoramidites therefore becomes a competitive differentiator for biotech firms developing individualized treatments. Additionally, the confluence of rapid genomic data generation and decreasing synthesis costs is fostering a feedback loop: as more patient genomes are sequenced, the need for high‑quality phosphoramidites rises, which in turn reduces synthesis turnaround times and accelerates clinical trial enrollment for targeted therapies.
The expansion of biotechnological research across academia, contract research organizations (CROs), and industrial biotech drives the utilization of dG(ibu) phosphoramidites in a broad spectrum of applications. Global key manufacturers—including Glen Research, ChemGenes, Bioneer, Thermo Fisher Scientific, Merck, BOC Sciences, TCI, Hongene Biotech, Biosynth Carbosynth, BLD Pharmatech, LGC Standards, Chemtour and Wuhu Huaren Science and Technology—collectively captured approximately 35 % of total market revenue in 2025. Their product portfolios span three purity tiers: ≥ 98 %, ≥ 99 % and other specialty grades, with the ≥ 99 % segment gaining traction among high‑throughput screening programs that demand ultra‑low error rates. By application, biotechnology companies account for roughly 58 % of market consumption, while research laboratories contribute about 32 %; the remaining share is driven by diagnostic assay developers and academic synthesis cores. Regionally, North America retains the largest share, buoyed by sustained federal funding for gene‑editing research, whereas Asia‑Pacific—led by China, Japan and South Korea—exhibits the fastest growth rate, reflecting aggressive national initiatives in synthetic biology. The report surveyed manufacturers, distributors and industry experts to capture trends in price volatility, supply‑chain resilience, and emerging regulatory frameworks. Findings highlight that while raw material cost pressures are modest, manufacturers are investing in advanced continuous‑flow reactors to enhance batch consistency and reduce waste. These strategic moves aim to safeguard supply for the expanding pipeline of oligonucleotide‑based therapeutics, ensuring that dG(ibu) phosphoramidites remain a cornerstone reagent in the next decade of biotechnological innovation.
North America currently holds the largest share of the global dG(ibu) Phosphoramidites market. The United States, home to a dense concentration of biotech and pharmaceutical firms, drives demand through extensive oligonucleotide research programs and an expanding portfolio of mRNA‑based therapeutics. The region benefits from a mature regulatory framework, strong intellectual‑property protection, and substantial public‑private R&D funding. Canada’s growing presence in genomic research and Mexico’s emerging contract manufacturing sector further reinforce North America’s leadership. High adoption of advanced synthesis platforms, coupled with the proximity to major academic hubs such as MIT, Stanford, and the Broad Institute, ensures sustained consumption of high‑purity dG(ibu) phosphoramidites. Moreover, the region’s supply chain resilience—characterized by well‑established distribution networks and proximity to key manufacturers like Glen Research and Thermo Fisher Scientific—helps maintain market dominance.
Key Highlights:
Asia‑Pacific is expected to register the fastest growth rate over the forecast horizon. China’s rapid expansion of its biotech ecosystem, reinforced by the “Made in China 2025” initiative, has led to a surge in oligonucleotide therapeutics development. Japan’s longstanding leadership in nucleic‑acid research and South Korea’s aggressive government incentives for RNA‑based drug platforms further boost demand. India’s growing contract research organization (CRO) sector and Southeast Asian nations’ investment in genomics infrastructure add momentum. The region’s large, cost‑competitive manufacturing base, combined with expanding academic collaborations, fuels a pipeline of new entrants seeking high‑purity dG(ibu) phosphoramidites for both discovery and commercial scale‑up.
Key Highlights:
European markets are experiencing a pronounced uplift in dG(ibu) phosphoramidite consumption as biotech infrastructure modernizes. The European Union’s Horizon Europe programme has allocated over €15 billion to genomic and RNA‑based research, spurring activity in Germany, the United Kingdom, France, and the Nordic countries. These nations host a high density of specialized laboratories focused on antisense, siRNA, and CRISPR technologies, all of which require dG(ibu) phosphoramidites of ≥99 % purity for precision synthesis. Regulatory harmonization through the European Medicines Agency (EMA) facilitates cross‑border collaborations, allowing companies to source reagents from multiple suppliers such as ChemGenes, BOC Sciences, and TCI. Additionally, the growing emphasis on personalized medicine and rare‑disease therapeutics drives demand for custom‑grade phosphoramidites, reinforcing Europe’s strategic importance in the global market.
Key Highlights:
In South America, Brazil and Argentina are emerging as pivotal investment hubs. Brazil’s São Paulo biotech corridor has attracted multinational pharma firms seeking to leverage local talent and favorable tax incentives. Argentina’s growing CRO landscape, supported by government grants for genomic innovation, is also driving demand for high‑quality phosphoramidites. In the Middle East & Africa, the United Arab Emirates and Saudi Arabia are accelerating their biotech ambitions through the UAE’s “Dubai Science Park” and Saudi Arabia’s “NEOM” biotech zone, both of which prioritize advanced nucleic‑acid synthesis capabilities. Turkey’s strategic position as a bridge between Europe and Asia further enhances its role as a distribution hub for the region.
Smart city initiatives across the globe are indirectly amplifying demand for dG(ibu) phosphoramidites by fostering a data‑driven health ecosystem. Integrated health‑monitoring platforms in smart cities require large‑scale genomic sequencing and real‑time pathogen surveillance, both of which depend on advanced oligonucleotide synthesis. Europe’s “Digital Europe” agenda and Asia‑Pacific’s “Smart City” programs allocate substantial budgets for public‑health genomics infrastructure, translating into higher procurement of high‑purity phosphoramidites for diagnostics and vaccine development. In North America, the convergence of tele‑medicine, AI‑enabled diagnostics, and urban health data platforms creates a sustained need for reliable synthesis reagents. Consequently, smart city projects act as catalysts for expanding the downstream demand chain of dG(ibu) phosphoramidites.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Glen Research, ChemGenes, Bioneer, Thermo Fisher Scientific, Merck, BOC Sciences, TCI, Hongene Biotech, Biosynth Carbosynth, BLD Pharmatech, LGC Standards, Chemtour, and Wuhu Huaren Science and Technology.
-> Key growth drivers include rapid expansion of mRNA and gene‑editing therapeutics, rising investment in nucleic‑acid drug development, and the demand for high‑purity (>98%) phosphoramidites.
-> Asia‑Pacific leads in manufacturing capacity, while North America dominates consumption due to a dense concentration of biotech firms.
-> Emerging trends include automation of oligonucleotide synthesis, green‑chemistry approaches reducing solvent waste, and the development of ultra‑high‑purity (>99%) phosphoramidites.
